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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
L-glutamine and growth or maintenance of muscle mass (ID 719, 722, 
3185), faster restoration of muscle glycogen stores after strenuous exercise 
(ID 434, 699, 701, 723, 1569), skeletal muscle tissue repair (ID 721), 
maintenance of normal neurological function (ID 662, 700), increased 
attention (ID 700, 1570), improvement of working memory (ID 700, 1570), 
maintenance of defence against pathogenic gastro-intestinal 
microorganisms (ID 452), gut protein synthesis (ID 701), decreasing gut 
permeability (ID 701), and stimulating immunological responses (ID 1568) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to L-glutamine and growth or maintenance of muscle mass, faster restoration of muscle 
glycogen stores after strenuous exercise, skeletal muscle tissue repair, maintenance of normal 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1221, EFSA-Q-2008-1239, EFSA-Q-2008-1449, 
EFSA-Q-2008-1486, EFSA-Q-2008-1487, EFSA-Q-2008-1488, EFSA-Q-2008-1506, EFSA-Q-2008-1508, EFSA-Q-
2008-1509, EFSA-Q-2008-1510, EFSA-Q-2008-2305, EFSA-Q-2008-2306, EFSA-Q-2008-2307, EFSA-Q-2008-3917, 
adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Gut/Immune: Jean-Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan 
Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. The 
members of the Claims Sub-Working Group on Weight Management/Satiety/Glucose and Insulin Control/Physical 
Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. The 
members of the Claims Sub-Working Group on Mental/Nervous System: Jacques Rigo, Astrid Schloerscheidt, Barbara 
Stewart-Knox, Sean (J.J.) Strain and Peter Willatts. 
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neurological function, increased attention and improvement of working memory, maintenance of 
defence against pathogenic gastro-intestinal microorganisms, gut protein synthesis, decreasing gut 
permeability, and stimulating immunological responses. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is L-glutamine. The Panel considers that 
L-glutamine is sufficiently characterised. 
Growth or maintenance of muscle mass 
The claimed effects are “increasing cell swelling, volumization”, “muscle protein metabolism” and 
“improves muscles metabolism”. The target population is assumed to be the general population. In the 
context of the proposed wordings, the Panel assumes that the claimed effects refer to the growth or 
maintenance of muscle mass. The Panel considers that growth or maintenance of muscle mass is a 
beneficial physiological effect. 
A claim on protein and growth or maintenance of muscle mass has already been assessed with a 
favourable outcome. 
No references were provided which addressed the effects of L-glutamine consumption on growth or 
maintenance of muscle mass. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and growth or maintenance of muscle 
mass, apart from the well established role of protein on the claimed effect. 
Faster restoration of muscle glycogen stores after strenuous exercise 
The claimed effects are “supporting glycogen replenishment”, “muscle function”, “metabolic stress, 
protein synthesis, gut permeability, carbohydrate metabolism”, and “supporting glucose homeostasis”. 
The target population is assumed to be adults performing strenuous exercise. In the context of the 
proposed wordings, clarifications from Member States and references provided, the Panel assumes 
that the claimed effects refer to the faster restoration of glycogen stores in skeletal muscle after 
strenuous exercise. The Panel considers that faster restoration of muscle glycogen stores after 
strenuous exercise might be a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the two studies from which conclusions 
could be drawn for the scientific substantiation of the claim did not show an effect of L-glutamine 
consumption on the restoration of muscle glycogen stores after strenuous exercise. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and faster restoration of muscle glycogen 
stores after strenuous exercise. 
Skeletal muscle tissue repair 
The claimed effect is “supporting exercise recovery”. The target population is assumed to be adults 
performing resistance exercise. In the context of the proposed wordings, the Panel assumes that the 
claimed effect refers to the rebuilding of structural protein within the skeletal muscle tissue after 
exercise that has caused muscle damage. The Panel considers that skeletal muscle tissue repair is a 
beneficial physiological effect. 
No references were provided which addressed the effects of L-glutamine consumption on skeletal 
muscle tissue repair in humans.  
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and skeletal muscle tissue repair. 
Maintenance of normal neurological function 
The claimed effects are “mental health” and “nervous system”. The target population is assumed to be 
the general population. In the context of the proposed wordings and the clarifications provided by 
Member States, the Panel assumes that the claimed effects refer to the maintenance of normal 
neurological function. The Panel considers that the maintenance of normal neurological function is a 
beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and maintenance of normal neurological 
function. 
Increased attention 
The claimed effect is “mental health”. The target population is assumed to be the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increased 
attention. The Panel considers that increased attention is a beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and increased attention. 
Improvement of working memory 
The claimed effect is “mental health”. The target population is assumed to be the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
improvement of working memory. The Panel considers that improvement of working memory is a 
beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and improvement of working memory. 
Maintenance of defence against pathogenic gastro-intestinal microorganisms 
The claimed effect is “maintains healthy gastrointestinal tract and immune functions in stressful 
conditions”. The target population is assumed to be the general population. In the context of the 
proposed wordings and the clarifications provided by Member States, the Panel assumes that the 
claimed effect refers to the maintenance of defence against pathogenic gastro-intestinal 
microorganisms. The Panel considers that maintenance of defence against pathogenic gastro-intestinal 
microorganisms is a beneficial physiological effect.  
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim.  
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and maintenance of defence against 
pathogenic gastro-intestinal microorganisms.  
Gut protein synthesis 
The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The target population is assumed to be the general population. In the context of the 
clarifications provided by Member States, the Panel assumes that the claimed effect refers to gut 
protein synthesis. The Panel considers that gut protein synthesis is not a beneficial physiological 
effect per se, but needs to be linked to a beneficial physiological or clinical outcome. The Panel notes 
that no evidence has been provided on the context in which the claimed effect could be considered as 
a beneficial physiological effect.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and a beneficial physiological effect 
related to gut protein synthesis. 
Decreasing gut permeability 
The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The target population is assumed to be the general population. In the context of the 
clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
decreasing gut permeability. The Panel considers that decreasing gut permeability is not a beneficial 
physiological effect per se, but needs to be linked to a beneficial physiological or clinical outcome. 
The Panel notes that no evidence has been provided on the context in which the claimed effect could 
be considered as a beneficial physiological effect.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and a beneficial physiological effect 
related to decreasing gut permeability. 
Stimulating immunological responses 
The claimed effect is “immune health”. The target population is assumed to be the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to stimulating various immunological responses such as increasing mononuclear cell 
proliferation, cytokine production and nasal IgA after exercise. The evidence provided does not 
establish that stimulation of mononuclear cell proliferation, cytokine production and nasal IgA is a 
beneficial physiological effect per se.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-glutamine and a beneficial physiological effect 
related to the stimulation of mononuclear cell proliferation, cytokine production and nasal IgA.  
KEY WORDS 
L-glutamine, muscle mass, glycogen stores, tissue repair, neurological function, attention, working memory, 
defence, gastro-intestinal, microorganisms, gut, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is L-glutamine.  
Glutamine is a conditionally indispensable amino acid provided by mixed dietary protein intakes from 
different sources. It can also be consumed as a food supplement. The content of L-glutamine in foods 
can be measured by established methods. 
The Panel considers that the food constituent, L-glutamine, which is the subject of the health claims, 
is sufficiently characterised.  
2. Relevance of the claimed effect to human health 
2.1. Growth or maintenance of muscle mass (ID 719, 722, 3185)  
The claimed effects are “increasing cell swelling/volumization”, “muscle protein metabolism” and 
“improves muscles metabolism”. The Panel assumes that the target population is the general 
population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the growth 
or maintenance of muscle mass. Failure to increase muscle mass during growth and development, and 
the loss of muscle mass at any age, will reduce muscle strength and power. 
The Panel considers that growth or maintenance of muscle mass is a beneficial physiological effect. 
2.2. Faster restoration of muscle glycogen stores after strenuous exercise (ID 434, 699, 701, 
723, 1569) 
The claimed effects are “supporting glycogen replenishment”, “muscle function”, “metabolic stress, 
protein synthesis, gut permeability, carbohydrate metabolism” and “supporting glucose homeostasis”. 
The Panel assumes that the target population is adults performing strenuous exercise.  
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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In the context of the proposed wordings, clarifications from Member States and references provided, 
the Panel assumes that the claimed effects refer to the faster restoration of glycogen stores in skeletal 
muscle after strenuous exercise.  
The Panel considers that faster restoration of muscle glycogen stores after strenuous exercise might be 
a beneficial physiological effect. 
2.3. Skeletal muscle tissue repair (ID 721) 
The claimed effect is “supporting exercise recovery”. The Panel assumes that the target population is 
adults performing resistance exercise.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
rebuilding of structural protein within the skeletal muscle tissue after exercise that has caused muscle 
damage.  
The Panel considers that skeletal muscle tissue repair is a beneficial physiological effect. 
2.4. Maintenance of normal neurological function (ID 662, 700) 
The claimed effect is “nervous system” and “mental health”. The Panel assumes that the target 
population is the general population. 
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of normal neurological function.  
The Panel considers that maintenance of normal neurological function is a beneficial physiological 
effect. 
2.5. Increased attention (ID 700, 1570) 
The claimed effect is “mental health”. The Panel assumes that the target population is the general 
population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increased 
attention (concentration).  
The Panel considers that increased attention is a beneficial physiological effect. 
2.6. Improvement of working memory (ID 700, 1570) 
The claimed effect is “mental health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
improvement of working memory.  
The Panel considers that improvement of working memory is a beneficial physiological effect. 
2.7. Maintenance of defence against pathogenic gastro-intestinal microorganisms (ID 452) 
The claimed effect is “maintains healthy gastrointestinal tract and immune functions in stressful 
conditions”. The Panel assumes that the target population is the general population.  
L-Glutamine related health claims 
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In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of defence against pathogenic gastro-
intestinal microorganisms. 
The Panel considers that maintenance of defence against pathogenic gastro-intestinal microorganisms 
is a beneficial physiological effect. 
2.8. Gut protein synthesis (ID 701) 
The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The Panel assumes that the target population is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to gut protein synthesis. 
The Panel considers that gut protein synthesis is not a beneficial physiological effect per se, but needs 
to be linked to a beneficial physiological or clinical outcome. The Panel notes that no evidence has 
been provided on the context in which the claimed effect could be considered as a beneficial 
physiological effect.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and a beneficial physiological effect related to gut protein synthesis. 
2.9. Decreasing gut permeability (ID 701) 
The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The Panel assumes that the target population is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to decreasing gut permeability. 
The Panel considers that decreasing gut permeability is not a beneficial physiological effect per se, 
but needs to be linked to a beneficial physiological or clinical outcome. The Panel notes that no 
evidence has been provided on the context in which the claimed effect could be considered as a 
beneficial physiological effect.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and a beneficial physiological effect related to decreasing gut 
permeability. 
2.10. Stimulating immunological responses (ID 1568) 
The claimed effect is “immune health”. The Panel assumes that the target population is the general 
population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to stimulating various immunological responses such as increasing mononuclear cell 
proliferation, cytokine production and nasal IgA after exercise. 
The Panel considers that the evidence provided does not establish that stimulation of mononuclear 
cell proliferation, cytokine production and nasal IgA is a beneficial physiological effect per se.  
L-Glutamine related health claims 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and a beneficial physiological effect related to the stimulation of 
mononuclear cell proliferation, cytokine production and nasal IgA. 
3. Scientific substantiation of the claimed effect 
The references provided for the scientific substantiation of these claims included textbooks and 
narrative reviews which did not provide original data for the scientific substantiation of the claim. 
Human, animal and in vitro studies on food constituents other than L-glutamine alone (e.g. branched-
chain aminoacids (BCAA); N-acetyl-cysteine; mixtures of whey protein plus BCAA or arginine plus 
L-glutamine; mixtures of soy lecithin, sodium dihydrogen phosphate, thiamin, pyridoxine and L-
glutamine; mixtures of glycine, niacin, and glutamine), on glutamine given intravenously, on health 
outcomes (e.g. treatment of chronic disease or pathological conditions, morbidity and mortality in pre-
term infants, use in enteral nutrition) unrelated to the claimed effects, or on the effects of intense 
training on plasma and tissue concentrations of L-glutamine, were also provided. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claims.  
3.1. Growth or maintenance of muscle mass (ID 719, 722, 3185) 
A claim on protein and growth or maintenance of muscle mass has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010).  
Glutamine is a component of dietary protein, and both endogenous and exogenous glutamine 
contribute to protein synthesis.  
No references which addressed the effects of L-glutamine consumption on growth or maintenance of 
muscle mass were provided. No evidence has been provided that L-glutamine in addition to normal 
protein intake has an additional role in muscle mass. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and growth or maintenance of muscle mass, apart from the well 
established role of protein on the claimed effect. 
3.2. Faster restoration of muscle glycogen stores after strenuous exercise (ID 434, 699, 701, 
723, 1569) 
Two references which assessed the effects of L-glutamine consumption on muscle glycogen stores 
after exercise were provided.  
In the study by Bowtell et al. (1999) seven male subjects participated in three trials, in each of which 
they received one of three different drinks by systematic rotation: 18.5 % (wt/vol) glucose polymer 
solution (containing glucose, maltose, maltotriose, tetrasaccharide, pentasaccharide and “higher 
sugars”), a solution containing 8 g glutamine, or 18.5 % glucose polymers containing 8 g glutamine. 
Tests were undertaken one month apart. On each test day, subjects followed a validated standard 
exercise protocol designed to deplete of glycogen both type I and type II muscle fibres. A muscle 
biopsy was taken from the quadriceps femoris muscle within 15 min of the end of exercise. Within 20 
min, a 2 h constant [1-
13
C]glucose intravenous infusion started at a rate of 8.5 mg/kg/h for the first 30 
min after a 9 mg/kg bolus of [1-
13
C]glucose. Subjects then consumed the test drinks (330 mL) within 
2 min of the start of the infusion. Second and third quadriceps femoris muscle biopsies were taken 
after 1 and 2 h of recovery. No significant differences with respect to the average rate of net muscle 
glycogen storage during the 2 h of recovery after exercise were observed between the test drinks. The 
Panel notes that this study does not show an effect of L-glutamine on the restoration of muscle 
glycogen stores after strenuous exercise. 
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In the study by Van Hall et al. (2000) eight trained subjects were studied during 3 h of recovery while 
consuming one of four drinks in random order. Drinks were ingested in three 500 mL boluses. Each 
bolus of the control drink contained 0.8 g/kg body weight of glucose. The other drinks contained the 
same amount of glucose and either 0.3 g/kg body weight of glutamine, or a wheat hydrolysate (26 % 
glutamine), or a whey hydrolysate (6.6 % glutamine). On each test day (7 days apart), subjects 
followed a validated standard exercise protocol for glycogen depletion. A biopsy was taken from the 
quadriceps muscle 15 min after the end of exercise, and the first bolus was taken immediately 
thereafter. The other boluses followed after 1 and 2 h of recovery. A second muscle biopsy was taken 
after 3 h of recovery. The rate of glycogen re-synthesis in skeletal muscle was not significantly 
different between the four test drinks. The Panel notes that this study does not show an effect of 
L-glutamine on the restoration of muscle glycogen stores after strenuous exercise.  
In weighing the evidence, the Panel took into account that the two studies from which conclusions 
could be drawn for the scientific substantiation of the claim did not show an effect of L-glutamine 
consumption on the restoration of muscle glycogen stores after strenuous exercise. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and faster restoration of muscle glycogen stores after strenuous exercise. 
3.3. Skeletal muscle tissue repair (ID 721) 
No references which addressed the effects of L-glutamine consumption on skeletal muscle tissue 
repair in humans were provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and skeletal muscle tissue repair. 
3.4. Maintenance of normal neurological function (ID 662, 700) 
No references which addressed the effects of L-glutamine consumption on neurological function were 
provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and maintenance of normal neurological function.  
3.5. Increased attention (ID 700, 1570)  
No references which addressed the effects of L-glutamine consumption on measures of attention were 
provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and increased attention.  
3.6. Improvement of working memory (ID 700, 1570) 
No references which addressed the effects of L-glutamine consumption on measures of working 
memory were provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and improvement of working memory. 
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3.7. Maintenance of defence against pathogenic gastro-intestinal microorganisms (ID 452) 
Rohde et al. (1996) investigated the effects of physical exercise (i.e. triathlon) on immune markers 
and serum amino acid concentrations in eight male tri-athletes. The Panel notes that this study did not 
report on L-glutamine intakes.  
Castell et al. (1996) studied ultra-marathon (n=27), marathon (n=88), middle-distance (10 and 15 km; 
n=41) runners and rowers (n=45) undergoing training. Both males and females were included. 
Glutamine (5 g in 330 mL mineral water) or placebo (maltodextrin) were given immediately after and 
2 h after a test exercise on a double-blind basis. Randomisation is not mentioned. The athletes were 
given a questionnaire to monitor infections according to specified symptoms for seven days after the 
test exercise. Gastro-intestinal infections were included for analysis in addition to airway infections. 
The incidence of infections in the seven-day period was only reported for marathon and ultra-
marathon runners. The Panel notes the lack of information about randomisation, that no detailed 
information about the questionnaires used for the diagnosis of infections was provided, that the 
number of non-responders and the gender distribution were not indicated, and that it is unclear why 
some sub-groups of athletes were excluded from the statistical analysis. The Panel considers that 
owing to important methodological limitations no conclusions can be drawn from this study for the 
scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-glutamine and maintenance of defence against pathogenic gastro-intestinal 
microorganisms. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, L-glutamine, which is the subject of the health claims, is sufficiently 
characterised. 
Growth or maintenance of muscle mass (ID 719, 722, 3185)  
 The claimed effects are “increasing cell swelling/volumization”, “muscle protein metabolism” 
and “improves muscles metabolism”. The target population is assumed to be the general 
population. Growth or maintenance of muscle mass is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and growth or maintenance of muscle mass, apart from the well established role 
of protein on the claimed effect. 
Faster restoration of muscle glycogen stores after strenuous exercise (ID 434, 699, 701, 723, 
1569) 
 The claimed effects are “supporting glycogen replenishment”, “muscle function”, “metabolic 
stress, protein synthesis, gut permeability, carbohydrate metabolism”, and “supporting 
glucose homeostasis”. The target population is assumed to be adults performing strenuous 
exercise. Faster restoration of muscle glycogen stores after strenuous exercise might be a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and faster restoration of muscle glycogen stores after strenuous exercise. 
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Skeletal muscle tissue repair (ID 721) 
 The claimed effect is “supporting exercise recovery”. The target population is assumed to be 
adults performing resistance exercise. Skeletal muscle tissue repair is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and skeletal muscle tissue repair. 
Maintenance of normal neurological function (ID 662, 700) 
 The claimed effects are “nervous system” and “mental health”. The target population is 
assumed to be the general population. Maintenance of normal neurological function is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and maintenance of normal neurological function. 
Increased attention (ID 700, 1570) 
 The claimed effect is “mental health”. The target population is assumed to be the general 
population. In the context of the proposed wordings, it is assumed that the claimed effect 
refers to increased attention. Increased attention is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and increased attention. 
Improvement of working memory (ID 700, 1570) 
 The claimed effect is “mental health”. The target population is assumed to be the general 
population. In the context of the proposed wordings, it is assumed that the claimed effect 
refers to improvement of working memory. Improvement of working memory is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and improvement of working memory.  
Maintenance of defence against pathogenic gastrointestinal microorganisms (ID 452) 
 The claimed effect is “maintains healthy gastrointestinal tract and immune functions in 
stressful conditions”. The target population is assumed to be the general population. 
Maintenance of defence against pathogenic gastro-intestinal microorganisms is a beneficial 
physiological effect.  
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and maintenance of defence against pathogenic gastro-intestinal microorganisms. 
Gut protein synthesis (ID 701) 
 The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The target population is assumed to be the general population. Gut protein 
synthesis is not a beneficial physiological effect per se, but needs to be linked to a beneficial 
physiological or clinical outcome. No evidence has been provided on the context in which the 
claimed effect could be considered as a beneficial physiological effect. 
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 A cause and effect relationship has not been established between the consumption of 
L-glutamine and a beneficial physiological effect related to gut protein synthesis. 
Decreasing gut permeability (ID 701) 
 The claimed effect is “metabolic stress, protein synthesis, gut permeability, carbohydrate 
metabolism”. The target population is assumed to be the general population. Decreasing gut 
permeability is not a beneficial physiological effect per se, but needs to be linked to a 
beneficial physiological or clinical outcome. No evidence has been provided on the context in 
which the claimed effect could be considered as a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and a beneficial physiological effect related to decreasing gut permeability. 
Stimulating immunological responses (ID 1568) 
 The claimed effect is “immune health”. The target population is assumed to be the general 
population. In the context of the clarifications provided by Member States, it is assumed that 
the claimed effect refers to stimulating various immunological responses such as increasing 
mononuclear cell proliferation, cytokine production and nasal IgA after exercise. The 
evidence provided does not establish that stimulation of mononuclear cell proliferation, 
cytokine production and nasal IgA is a beneficial physiological effect per se. 
 A cause and effect relationship has not been established between the consumption of 
L-glutamine and a beneficial physiological effect related to the stimulation of mononuclear 
cell proliferation, cytokine production and nasal IgA.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1221, 
EFSA-Q-2008-1239, EFSA-Q-2008-1449, EFSA-Q-2008-1486, EFSA-Q-2008-1487, EFSA-Q-2008-
1488, EFSA-Q-2008-1506, EFSA-Q-2008-1508, EFSA-Q-2008-1509, EFSA-Q-2008-1510, EFSA-Q-
2008-2305, EFSA-Q-2008-2306, EFSA-Q-2008-2307, EFSA-Q-2008-3917). The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c). 
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
 
L-Glutamine related health claims 
 
21 EFSA Journal 2011;9(6):2225 
APPENDIX C 
Table 1. Main entry health claims related to glutamine, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
434 Glutamine Supporting glycogen 
replenishment 
Glutamine may support 
muscle glycogen 
replenishment 
followingexhaustive exercise. 
Conditions of use 
- Amount of consumption (value): 50 Milligramm (mg). Amount of consumption (plaintext): 
mg/kg KG p.Tag. Upper limit (value): 900 Milligramm (mg). Other condition: mg/kg täglich 
- The product must contain at least 5 gram Glutamine per serving. Claim to be used for foods 
for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
452 L-glutamine Maintains healthy 
gastrointestinal tract and 
immune functions in 
stressful conditions 
Clarification provided 
Supports a healthy immune 
system: decrease in 
infections among treated 
athletes, mechanism may be 
linked to neutrophils 
Glutamine supports a healthy 
digestive system and 
contributes to strengthen the 
natural defences 
Conditions of use 
- Healthy adults concerned with maintaining healthy gastrointestinal tract and immune 
functions in stressful conditions. AMOUNT RECOMMENDATION: Min 5 g glutamine per 
day 
ID Food or Food constituent Health Relationship Proposed wording 
662 L-Glutamine Nervous system 
Clarification provided 
Influence on nervous system: 
for the better performance of 
the nervous system and the 
brain /constituent of 
gluthathione, purines, amino 
sugars, precursor of GABA 
(g-amino butyric acid) 
Glutamine contributes to the 
healthy function of the 
nervous system and the brain. 
Conditions of use 
- Schulkinder, Erwachsene. Amount of consumption: 1000 Milligramm (mg) 
- Amount of consumption: 100 mg/Tag. Other condition: Mind. 100 mg täglich 
- Other condition: Vor allem in Kombination mit anderen Aminosäuren wie z.B. Serin sowie 
den Vitaminen B12, B1, B2 und B6 
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- 225 mg,;15% of the lower (1500 mg) therapeutic dose ;(Martindale pp. 1785-86) 
ID Food or Food constituent Health Relationship Proposed wording 
699 Glutamine Muscle function 
Clarification provided 
Increases blood glutamine 
levels, which is reduced 
during exercise 
Skeletal muscle represents the 
greatest store of glutamine in 
the body/muscle tissue is an 
important source of 
glutamine/high intensity 
exercise decreases plasma 
glutamine levels 
anaerobic training can deplete 
the glutamine pool/prolonged 
exercise such as marathon 
running decreases glutamine 
levels/supplementation can 
maintain glutamine levels 
during intense exercise/can 
abolish the exercise related 
decline 
restores blood glutamine 
levels post exercise/helps 
maintain optimal health after 
training/helps keep athletes 
healthy after intense 
exercise/optimizing blood 
glutamine levels helps 
enhance muscle adaptation to 
intense exercise 
/reduced glutamine levels 
decreases the adaptive 
response to intense 
exercise/helps enhance 
glycogen storage/helps 
increase carbohydrate storage 
Conditions of use 
- 50 - 900 mg/kg per day 
ID Food or Food constituent Health Relationship Proposed wording 
700 Glutamine Mental health - Constituent of 
gluthathione, purines, 
amino sugars, precursor of 
GABA (g-amino butyric 
acid)/supports 
concentration and mental 
performance under 
conditions of mental or 
physical exertion/ 
- helps to maintain working 
memory and brain 
performance in aging 
adults/plays an important 
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role in healthy nerve 
function through the 
central nervous system 
including the brain 
Conditions of use 
- Min 100 mg per day 
ID Food or Food constituent Health Relationship Proposed wording 
701 Glutamine and glutamine 
peptide 
Metabolic stress/protein 
synthesis/gut 
permeablity/carbohydrate 
metabolism 
Clarification provided 
Contributes to gut protein 
synthesis. 
Decreases permeability of 
gut cells. 
Increases/Replenishes 
carbohydrate stores in the 
muscle and the liver 
Extra dietary supply of 
glutamine restores plasma 
glutamine levels after 
metabolic stress/contributes to 
gut protein synthesis/help 
decrease permeability of gut 
cells/helps to replenish 
carbohydrate stores in the 
muscle and the liver 
 
Conditions of use 
- min.5 g glutamine per day 
ID Food or Food constituent Health Relationship Proposed wording 
719 Glutamine Increasing cell swelling / 
volumization 
Glutamine may improve 
intestinal water and electrolyte 
absorption 
Glutamine can help volumize 
muscle cells 
Glutamine may increase cell 
swelling (volume) 
Conditions of use 
- The product must contain at least 5 gram Glutamine per serving 
- Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
721 Glutamine Supporting exercise recovery Glutamine is considered 
essential for repair and 
recovery 
Glutamine can aid In muscle 
tissue repair 
Conditions of use 
- The product must contain at least 5 gram Glutamine per serving 
- Claim to be used for foods for active individuals 
L-Glutamine related health claims 
 
24 EFSA Journal 2011;9(6):2225 
ID Food or Food constituent Health Relationship Proposed wording 
722 Glutamine Muscle protein metabolism Glutamine supports muscle 
cells 
Glutamine supports muscle 
protein metabolism 
Conditions of use 
- The product must contain at least 5 gram Glutamine per serving 
- Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
723 Glutamine Supporting glucose 
homeostasis 
Glutamine may support 
glucose homeostasis during 
and after exercise 
Conditions of use 
- The product must contain at least 5 gram Glutamine per serving  
- Claim to be used for foods for active individuals 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1568 Glutamine Immune health 
Clarification provided 
Immune health. 
Supports the immune system: 
Glutamine supplementation 
increases mononuclear cell 
proliferation, cytokine 
production and nasal IgA 
after exercise. 
Supports the immune system 
-is an important nutrient for 
those cells requiring rapid 
renewal such as immune cells 
(e.g. lymphocytes) 
-is an important fuel for 
rapidly dividing cells, 
including those of the immune 
system 
-supplementation contributes 
to immune function 
-contributes to the immune 
response to exercise 
Conditions of use 
- 50-400 mg/kg per day. The product must contain at least 5 gram Glutamine per serving. 
Claim to be used for foods for active individuals 
- Immunonutrition 
ID Food or Food constituent Health Relationship Proposed wording 
1569 Glutamine Muscle function 
Clarification provided 
Supports muscle function: 
Exercise decreases plasma 
glutamine concentrations. 
Glutamine supplementation 
can maintain plasma 
Skeletal muscle represents the 
greatest store of glutamine in 
the body 
-muscle tissue is an important 
source of glutamine 
-high intensity exercise 
decreases plasma glutamine 
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glutamine concentrations 
during intense exercise: 
Abolishing the decline in 
plasma glutamine and 
enhancing plasma glutamine 
levels. 
Glutamine supplementation 
reduces the risk of infections 
after training, helping 
athletes avoid infections after 
intense exercise. 
After exercise glutamine 
supplementation may 
enhance glycogen and 
carbohydrate storage in 
skeletal muscle following 
exercise. 
Reducing the decline in 
blood glutamine levels after 
training reduces breakdown 
of body tissue 
levels 
-anaerobic training can deplete 
the glutamine pool 
-prolonged exercise such as 
marathon running decreases 
glutamine levels 
-supplementation can maintain 
glutamine levels during 
intense exercise 
-can abolish the exercise 
related decline in glutamine 
stores 
-enhances glutamine levels 
-restores blood glutamine 
levels post exercise 
-helps maintain optimal health 
after training 
-helps keep athletes healthy 
after intense exercise 
-optimizing blood glutamine 
levels helps enhance muscle 
adaptation to intense exercise 
-reduced glutamine levels 
decreases the adaptive 
response to intense exercise 
-helps enhance glycogen 
storage 
-helps increase carbohydrate 
storage 
Conditions of use 
- 50 - 900 mg/kg per day 
- Sportler–Tagesdosis L-Glutamin: 500 mg– 
Comments from Member States 
Note the Cion from submitter: Submitter initally sent these as separte claims to the CIAA, the 
claims have since become amalgamated into one. Please separate and health relationships 
amended as indicated 
ID Food or Food constituent Health Relationship Proposed wording 
1570 Glutamine Mental health - supports concentration and 
mental performance under 
conditions of mental or 
physical exertion 
- helps to maintain working 
memory and brain 
performance in aging 
adults 
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Conditions of use 
- 225 mg,;15% of the lower (1500 mg) therapeutic dose ;(Martindale pp. 1785-86) 
- Min 100 mg per day 
- Tagesdosis L-Glutaminsäure: 500 mg– Erwachsene 
- Gesamtbevölkerung 
ID Food or Food constituent Health Relationship Proposed wording 
3185 Glutaminian glutamine improves muscles 
metabolism 
- glutamine improves body 
metabolism  
Conditions of use 
- (twice a day 170,2 mg) 
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GLOSSARY AND ABBREVIATIONS 
BCAA  Branched-chain amino acids 
